Avicanna Files Patent For New Cannabinoid-Based Epilepsy Medication
Avicanna Inc., (TSX: AVCN) (OTCQX: AVCNF) a biopharmaceutical company focused on cannabinoid-based medicines, has filed a provisional patent application that aims to patent the use of a novel cannabinoid formulation for reducing or eliminating seizures and sudden death in epilepsy.
Does TerrAscend’s Acquisition Of Gage Growth Dilute Other Parts Of The Company?
The month of September began with news of TerrAscend (Canadian: TER) (OTCQX: TRSSF) signing a definitive agreement to acquire Gage G
Zelira Lands In Germany With Distribution Agreement For Cannabinoid Sleep Medication
Australia-based Zelira Therapeutics Ltd. (OTCQB: ZLDAF), a company developing cannabinoid-based medicines, announced that it is entering the German market via a 5-year exclusive distribution agreement with IM Cannabis Corp. (CSE: IMCC) (NASDAQ:
Delic Signs $10M Merger With Chain Of Ketamine Clinics
Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF), a company in the psychedelics space, has entered into a binding merger agreement with Ketamine Wellness Centers Arizona LLC, a company operating 10 ketamine infusion treatment clinics across the country.
Psyched: First Active Psychedelics ETF Hits NYSE, Compass Dives Into Novel Molecules, Atai Subsidiary Launches Phase 2a Trial
AdvisorShares Launches First NYSE-listed Actively-managed Psychedelics ETF
On Thursday, AdvisorShares launched the country’s first actively managed ETF covering the psychedelics sector.
Nasdaq Welcomes New Psychedelics Company In $23M M&A Transaction
The psychedelics sector has closed one of its largest M&As since its inception.
Want Quick Exposure To The Psychedelics Sector? Check Out This New Active ETF
Retail investors are getting new tools for gaining exposure to the booming medicinal psychedelics industry.
On Thursday, AdvisorShares launched the country’s first actively managed ETF covering the psychedelics sector.
Compass: Psychedelics Unicorn Expands Portfolio Beyond Psilocybin Into Psychedelics 2.0
Psychedelics biotech company Compass Pathways (NASDAQ: CMPS) has purchased an intellectual property portfolio that includes patent applications for a variety of psychedelic and empathogenic substances.
From Cannabis MSO To Drug Development: Goodness Growth Wants To Understand Traditional Psychedelics Use
Resurgent Biosciences, a subsidiary of Goodness Growth Holdings, Inc. (CSE: GDNS) (OTCQX: GDNSF), is launching a survey study that will look into the varying effects of entheogen and psychedelic experiences for therapeutic, religious and spiritual purposes.